Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as DCGO and PARK. With a market capitalization of $59.07M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against DCGO's 19.99% and PARK's 14.77%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
